Results 11 to 20 of about 18,364 (184)
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Drugs in R&D, 2010 In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and bupropion SR 360 mg.
openaire +2 more sources
Naltrexone Protects Against Lipopolysaccharide/D-Galactosamine–Induced Hepatitis in Mice
Journal of Pharmacological Sciences, 2008 Naltrexone, an opioid receptor antagonist, has been claimed to have anti-inflammatory and immunomodulatory effects both in vitro and in vivo.
Chien-Chuan Wang +5 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2022 Sarah Dahlberg,1 Ellen T Chang,1 Sheila R Weiss,1 Pamela Dopart,1 Errol Gould,2 Mary E Ritchey3 1Exponent, Inc, Menlo Park, CA, 94025, USA; 2Currax Pharmaceuticals LLC., Brentwood, TN, 37027, USA; 3Med Tech Epi, LLC., Philadelphia, PA, 19147 ...
Dahlberg S +5 more
doaj
The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study
Frontiers in Psychiatry, 2010 These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given that one of the most well-established mechanisms of action of naltrexone involves blunting of alcohol reward, it is hypothesized that naltrexone should be ...
Lara Ray +2 more
doaj +1 more source
Exploring genetic predictors of naltrexone treatment response in opioid use disorder
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2019 Purpose: The present study was aimed to evaluate the effect of the opioid receptors genes and dopamine system genes polymorphisms on the treatment outcomes of opioid dependence with implantable and oral naltrexone in randomized double blinded double ...
Е. A. Blokhina . +6 more
doaj +1 more source
Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence
Substance Abuse: Research and Treatment, 2011 Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone.
Kimberly L. Kjome, F. Gerard Moeller
doaj +1 more source
Addiction Neuroscience, 2023 The non-selective opioid receptor antagonist, naltrexone is one of the most prescribed medications for treating alcohol and opioid addiction. Despite decades of clinical use, the mechanism(s) by which naltrexone reduces addictive behavior remains unclear.
Cory N. Spencer +5 more
doaj +1 more source
Indian Dermatology Online Journal, 2019 Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication.
Sidharth Sonthalia +3 more
doaj +1 more source
Journal of Scientific Innovation in Medicine, 2023 Background: Nitrous oxide (N2O) is a non-regulated substance with increasing prevalence as a drug of abuse. N2O abuse is associated with both neurological and psychiatric sequelae, including psychotic symptoms.
Paige Juliet Staudenmaier +3 more
doaj +1 more source